Delivery Order SPE2DX22D0049-SPE2D826FA3UG

AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $47,744.34 on January 19, 2026, by the Defense Logistics Agency's Medical Supply Chain. This firm fixed-price, competitively awarded delivery order is a child award under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The contract carries no set-aside designation and is ultimately scheduled for completion by January 20, 2026. As a critical vendor in the federal pharmaceutical supply chain, AmerisourceBergen supplies a comprehensive portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems, including brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains.

AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc. (doing business as AmerisourceBergen), which holds the parent IDC with the Defense Logistics Agency. Cencora maintains a substantial $999,999,999.00 IDC with DLA Troop Support Medical extending through December 2031, serving as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally. The DLA Troop Support is planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple awards for separate regions, potentially involving at least three different contractors, positioning AmerisourceBergen to continue serving critical federal healthcare customers including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.